Is Eli Lilly Stock a Buy Right Now?

Impact · against what's priced in

The article provides no new catalysts for Eli Lilly, as the mentioned drivers—retatrutide's pipeline progress and margin improvements—are already explicitly accounted for or specifically declined by the current market price. The news confirms the existing trajectory without shifting the valuation assumptions.

LLY+0.00

Already priced in

The price assumes

Revenue guidance of $85–87 billion for 2026

The article's mention of growing quickly and expanding access at lower prices aligns with the existing growth trajectory the market already assumes for 2026.

What LLY's price assumes · Sep 10

• valuation▲1%
• healthcare
• pharmaceuticals
• LLY
• drug pipeline
• margins

Top 1 mover · tap to explore